MaxCyte share price logo

MaxCyte

NASDAQ: MXCT

$1.33

+0.03

(+2.69%)

Live

as on

MaxCyte Stock Performance

as on October 21, 2026 at 5:15 am IST

  • Day's Low

    Day's High

    $1.29
    $1.35
    downward going graph

    3.01%

    Downside

    1.50%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.64
    $1.81
    downward going graph

    51.62%

    Downside

    35.71%

    Upside

    downward going graph

MaxCyte share price movements today

Previous Close
$1.30
Open
$1.30
Volume
2.4M
Market Cap
$134.2M
Day's Low - High
$1.29 - $1.35
52 Week Low - High
$0.64 - $1.81

MaxCyte Historical Returns

1 Month Return
+ 9.24 %
3 Month Return
+ 11.11 %
1 Year Return
-25.71 %
3 Year Return
-58.33 %
5 Year Return
-88 %

MaxCyte Stock Fundamentals & Key Indicators

Check MaxCyte market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$134.2M

EPS (TTM)

-0.3343

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.89

Industry PE ratio

-4.98

PEG Ratio

-0.15

EBITDA

-30.8M

Revenue (TTM)

31.1M

Profit Margin

79.43%

Return On Equity TTM

-21.01%

MaxCyte vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MaxCyte with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
MaxCyte image
MaxCyte
Buy$134.2M-88.00%-3.8979.43%0.00%
Medtronic image
Medtronic
Buy$121.2B-23.83%23.1766.69%3.02%
Edwards Lifesciences image
Edwards Lifesciences
Buy$49.9B-24.55%49.7777.98%0.00%
Stryker image
Stryker
StrongBuy$113.0B8.83%30.2865.17%1.19%
Abbott Laboratories image
Abbott Laboratories
StrongBuy$181.5B-15.61%33.7256.80%2.40%
See all

Stock Returns calculator for MaxCyte Stock including INR - Dollar returns

The MaxCyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

MaxCyte investment value today

Current value as on today

₹82,102

Returns

-₹17,898

(-17.9%)

Returns from MaxCyte Stock

-₹24,000 (-24%)

Dollar Impact

₹6,102 (+6.1%)

Analyst Recommendation on MaxCyte Stock

Based on 3 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 3 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for MaxCyte. Average target price of $4.11

MaxCyte Share Price Target

Get share price movements and forecasts by analysts on MaxCyte.

What analysts predicted

67.64%UPSIDE

Target Price

$4.11

Current Price

$1.33

Analyzed by

3 Analysts

High

$4

Target

$4.11

Low

$4

MaxCyte target price $4.11, a slight upside of 67.64% compared to current price of $1.33. According to 3 analysts rating.

Indian Investors' Interest in MaxCyte Stock

Search interest for MaxCyte Stock has increased by 184% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:184% versus previous 30 day period

MaxCyte Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
11
10
8
8
10
8
6
7
9
7
Gross Profit
9
8
6
6
8
6
6
5
7
5
Operating Income
-12
-11
-14
-12
-12
-14
-10
-7
-6
-10
EBITDA
-8
-8
-10
-9
-8
-11
-11
-8
-3
-7
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Net Profit Margin
87.63%
85.73%
76.38%
73.76%
85.59%
82.14%
92.44%
77.95%
73.22%
76.96%

MaxCyte Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
13
16
21
26
33
44
41
38
33
Gross Profit
12
14
19
23
30
39
36
31
26
Operating Income
-9
-8
-12
-11
-18
-27
-48
-51
-45
EBITDA
-9
-7
-11
-9
-16
-20
-33
-36
-39
Interest Expense
0
0
0
0
1
0
-
-
-
Depreciation
0
0
0
1
1
2
4
4
5
Income Before Tax
-9
-8
-12
-11
-19
-23
-37
-41
-44
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-9
-8
-12
-11
-19
-23
-37
-41
-44
Net Profit Margin
89.61%
88.96%
88.44%
89.43%
89.24%
88.48%
88.51%
81.62%
81.16%

MaxCyte Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Operating Cash Flow
-10
-4
-4
-7
-14
-9
-7
-2
-8
-4
Investing Cash Flow
-14
19
3
-1
9
1
5
9
2
6
Financing Cash Flow
0
0
0
0
0
0
0
0
0
-1
Change in Cash
-24
15
0
-9
-4
-8
-2
7
-5
0

MaxCyte Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-9
-8
-12
-11
-19
-23
-37
-41
-44
Operating Cash Flow
-9
-10
-8
-8
-10
-14
-21
-27
-34
Investing Cash Flow
0
-3
0
-16
-195
-24
54
6
25
Financing Cash Flow
23
0
12
28
234
2
2
2
0
Change in Cash
13
-14
3
3
29
-36
35
-18
-7

Global Institutional Holdings in MaxCyte

Check out the Institutions with significant holdings in MaxCyte.

Funds
Holdings
Vanguard
4.11%
VANGUARD INDEX FUNDS
3.79%
Fidelity Salem Street Trust
1.09%
FINANCIAL INVESTORS TRUST
1.02%
Fidelity Concord Street Trust
0.85%
See all

MaxCyte News & Key Events

  • img

    Today's Timeline - 14 October

    Wed, 05:55 PM

    -

    MaxCyte raises FY26 revenue guidance to $34M from $30M-$32M, reflecting strong core business performance.

    Wed, 05:56 PM

    -

    MaxCyte reports preliminary Q3 revenue of $8.1M, exceeding expectations and raising growth outlook for the second half of 2026.

Insights on MaxCyte

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, MXCT stock has moved up by 34.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 15.8% return, outperforming this stock by 41.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Medtronic plc has given 25.5% return, outperforming this stock by 83.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -4.75M → -8.87M (in $), with an average decrease of 86.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 9.65M → 7.27M (in $), with an average decrease of 24.7% per quarter

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
OrganisationMaxCyte
Headquarters9713 Key West Avenue, Rockville, MD, 20850, US
IndustryBiotechnology
CEOMaher Masoud

Key Management of MaxCyte

Name

Title

Ms. Jill Mayer

Senior Vice President of Human Resources

Mr. Maher Masoud

President, CEO & Executive Director

Mr. Parmeet Ahuja

Chief Financial Officer

Mr. Jay Gelfman

Chief Operations Officer

Ms. Ana-Paula Martins Fernandes

Senior Vice President of Global Sales

Mr. Sidharth Kapileshwar

Chief Corporate Development Officer

FAQs

What is MaxCyte share price today?

MaxCyte share price today is $1.33 as on . MaxCyte share today touched a day high of $1.35 and a low of $1.29.

What is the 52 week high and 52 week low for MaxCyte share?

MaxCyte share touched a 52 week high of $1.81 on and a 52 week low of $0.64 on . MaxCyte stock price today i.e. is trending at $1.33,which is 26.32% down from its 52 week high and 106.71% up from its 52 week low.

What is MaxCyte's market capitalisation today?

MaxCyte market capitalisation is $0.00T as on .

How to invest in MaxCyte Stock (MXCT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MaxCyte on INDmoney app. Click on Buy button.

What is the minimum amount required to buy MaxCyte Stock (MXCT) from India?

Indian investors can start investing in MaxCyte (MXCT) shares with as little as ₹94.93000030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.30 in MaxCyte stock (as per the Rupee-Dollar exchange rate as on ). Based on MaxCyte share’s latest price of $1.33 as on October 20, 2026 at 11:45 pm IST, you will get 7.5188 shares of MaxCyte. Learn more about fractional shares .

What are the returns that MaxCyte has given to Indian investors in the last 5 years?

MaxCyte stock has given -88% share price returns and 26.42% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?